Top

Journal of Endocrinological Investigation

Published in:

01-08-2020 | COVID-19 | Opinion

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic

Authors: L. Bartalena, L. Chiovato, C. Marcocci, P. Vitti, E. Piantanida, M. L. Tanda

Published in: Journal of Endocrinological Investigation | Issue 8/2020

Excerpt

The Coronavirus disease 2019 (COVID-19) pandemic has prompted reflections and statements on the management of endocrine and metabolic disorders, including diabetes mellitus, obesity, adrenal insufficiency [1, 2], as well as on the way COVID-19 outbreak might affect our daily clinical practice after the pandemic will be over [3]. …

Puig-Domingo M, Marazuela M, Giustina A (2020) COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Eur J Endocrinol 68(1):2–5. https://doi.org/10.1007/s12020-020-02294-5 CrossRef

Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pofi R, Hasenmajer V, Venneri MA, Sbardella E, Simeoli C, Scaroni C, Lenzi A (2020) COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion in steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020 April 25 [Online ahead of print] https://doi.org/10.1007/s40618-020-01266-w

Trimarchi F (2020) An invisible hand has guided clinical endocrinology toward an unexpected future. J Endocrinol Invest. 2020 April 20 [Online ahead of print] https://doi.org/10.1007/s40618-020-01256-y

Smith TJ, Hegedus L (2016) Graves’ disease. N Engl J Med 375(16):1552–1565. https://doi.org/10.1056/nejmra1510030 CrossRefPubMed

Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L (2018) Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425–1432. https://doi.org/10.1007/s40618-018-0918-9 CrossRefPubMed

Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7(4):167–186. https://doi.org/10.1159/000490384 CrossRefPubMedPubMedCentral

Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, Brix TB, Hegedus L (2017) Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 102(7):2301–2309. https://doi.org/10.1210/jc.2017-00166 CrossRefPubMed

Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan D, Draman MS, Tennant B, Green J, Sayers A, French R, Lazarus JH, Premawardhana LD, Dayan CM (2019) Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 7(4):278–287. https://doi.org/10.1016/s2213-8587(19)30059-2 CrossRefPubMed

Akamizu T (2018) Thyroid storm: a Japanese perspective. Thyroid 28(1):32–40. https://doi.org/10.1089/thy.2017.0243 CrossRefPubMedPubMedCentral

10.

Azizi F, Malbbosbaf R (2019) Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest 42(11):1273–1283. https://doi.org/10.1007/s40618-019-01054-1 CrossRefPubMed

11.

Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest 39(10):1105–1114. https://doi.org/10.1007/s40618-016-0505-x CrossRefPubMed

12.

Bukhari S, Khan M, Kumar N, Mohan V (2017) Increased risk for thionamide-induced agranulocytosis in elderly patients: a case presentation and literature review. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-220924 CrossRefPubMedPubMedCentral

13.

Alfadhli E, Gianoukakis AG (2011) Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid 21(3):215–220. https://doi.org/10.1089/thy.2010.0159 CrossRefPubMed

14.

Hodak SP, Huang C, Clarke D, Burman KD, Jonklaas J, Janicic-Kharic N (2006) Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 16(7):291–295. https://doi.org/10.1089/thy.2006.16.691 CrossRef

15.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5(1):9–26. https://doi.org/10.1159/000443828 CrossRefPubMedPubMedCentral

16.

Jespersen S, Nyygard B, Ostergaard Kristensen L (2015) Methylprednisolone pulse treatment of Graves’ ophthalmopathy is not associated with secondary adrenocortical insufficiency. Eur Thyroid J 4(4):222–225. https://doi.org/10.1159/000440834 CrossRefPubMedPubMedCentral

Title: Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
Authors: L. Bartalena
L. Chiovato
C. Marcocci
P. Vitti
E. Piantanida
M. L. Tanda
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: COVID-19
Hyperthyroidism
Glucocorticoid
Propylthiouracil
Agranulocytosis
Published in: Journal of Endocrinological Investigation / Issue 8/2020
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-020-01293-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2020

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency

Schoolchildren thyroid volume in North Macedonia: data from a national survey in an iodine-sufficient country

Metabolomics and inflammation in polycystic ovary syndrome

A goitrous model for Bartolomeo Vivarini (1432–1499)

Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity

A case of subacute thyroiditis associated with Covid-19 infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials